

A circular stamp from the Office of Intellectual Property and Trade (OIPE). The text "OIPE" is at the top, "JCI-27" is at the top right, "AUG 17 2001" is in the center, and "PATENT &amp; TRADE MARKS OFFICE" is at the bottom. A small square box with the number "4" is to the left of the stamp. Below the stamp, the text "of 1993 and persons are required to" is partially visible.

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

<b>Application Number</b>	09/230,195
<b>Filing Date</b>	December 10, 1999
<b>First Named Inventor</b>	Rybak, <i>et al.</i>
Group Art Unit	1633
<b>Examiner Name</b>	Eleanor Sorbello
<b>Attorney Docket Number</b>	015280-284100US

(use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

[illegible]

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	AA	Europe	0334301	A1	VIAGNE, INC.	09/27/89	pg. 13, col. 23, ln. 32 - col. 24, ln 8; pg. 14, col. 26, ln. 47; pg. 15, col. 27, ln. 1	<input type="checkbox"/>
	AB	Europe	0334301	B1	CHIRON CORP	09/27/89		<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>

Edwards

10-31-01

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

SF 1239052 v1


TECH CENTER 1600/2900

AUG 21 2007

RECEIVED

Please type a plus sign (+) inside this box

+



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	09/230,195
Filing Date	December 10, 1999
First Named Inventor	Rybak, et al.
Group Art Unit	1633
Examiner Name	Eleanor Sorbello
Attorney Docket Number	015280-284100US

TECH CENTER 1600/2900

AUG 21 2001

RECEIVED

## **OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JS	AC	Akkina, et al. "High-Efficiency Gene Transfer into CD34 <sup>+</sup> Cells with a Human Immunodeficiency Virus Type 1-Based Retroviral Vector Pseudotyped with Vesicular Stomatitis Virus Envelope Glycoprotein G" <i>J. of Virology</i> 4/96 Vol. 70 (4) pp. 2581-2585	<input type="checkbox"/>
	AD	Bahner, et al. "Comparison of trans-Dominant Inhibitory Mutant Human Immunodeficiency Virus Type 1 Genes Expressed by Retroviral Vectors in Human T Lymphocytes" <i>J. of Virology</i> 6/93 Vol. 67 (6) pp. 3199-3207	<input type="checkbox"/>
	AE	Brenner, Malcom, K. "Gene Transfer into Human Hematopoietic Progenitor Cells: A Review of Current Clinical Protocols" <i>J. of Hematotherapy</i> (1993) Vol. 2 pp. 7-17	<input type="checkbox"/>
	AF	Chang, et al. "Regulation by HIV Rev Depends upon Recognition of Splice Sites" <i>Cell</i> 12/1989 Vol. 59 pp. 789-795	<input type="checkbox"/>
	AG	D'Agostino, et al. "The Rev Protein of Human Immunodeficiency Virus Type 1 Promotes Polysomal Association and Translation of gag/pol and vpu/env mRNAs" <i>Molecular and Cellular Biology</i> 3/92 Vol. 12 (3) 1375-1386	<input type="checkbox"/>
	AH	Felber, et al. "Rev Protein of Human Immunodeficiency Virus Type 1 Affects the Stability and Transport of the Viral mRNA" <i>Proc. Natl. Acad. Sci.</i> 03/1989 Vol. 86 pp.1495-1499	<input type="checkbox"/>
	AI	Feinberg, et al. "Intracellular Immunization: Trans-Dominant Mutants of HIV Gene Products as Tools for the Study and Interruption of Viral Replication" <i>AIDS Research and Human Retroviruses</i> (1992) Vol. 8 (6) pp. 1013-1022	<input type="checkbox"/>
	AJ	Ghattas, et al. "The Encephalomyocarditis Virus Internal Ribosome Entry Allows Efficient Coexpression of Two Genes from a Recomb Provirus in Cultured Cells and in Embryos" <i>Molecular and Cellular Biology</i> 12/91 Vol 11 pp. 5848-5859	<input type="checkbox"/>
	AK	Hsieh, et al. "Improved Gene Expression by a Modified Bicistronic Retroviral Vector" <i>Biochemical and Biophysical Research Communication</i> 09/1995 Vol. 214 (3) pp. 910-917	<input type="checkbox"/>
	AL	Itoh, et al. "HTLV-1 rex and HIV-1 rev Act Through Similar Mechanisms to Relieve Suppression of Unspliced RNA Expression" <i>Oncogene</i> (1989) Vol. 4 pp. 1275-1279	<input type="checkbox"/>
✓	AM	Levine, et al. "Efficient Gene Expression in Mammalian Cells from a Dicistronic Transcriptional Unit in an Improved Retroviral Vector" <i>Gene</i> (1991) Vol. 108 pp. 167-174	<input type="checkbox"/>

Examiner Signature	<i>E. Sorbello</i>	Date Considered	10-31-01
--------------------	--------------------	-----------------	----------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
SF 1239052 v1

Please type a plus sign (+) inside this box

+

AUG 17 2001

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 3

## **Complete if Known**

Application Number	09/230,195
Filing Date	December 10, 1999
First Named Inventor	Rybak, et al.
Group Art Unit	1633
Examiner Name	Eleanor Sorbello
Attorney Docket Number	015280-284100US

## **OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ES	AN	Moore, Malcolm, A.S. "Ex Vivo Expansion and Gene Therapy Using Cord Blood CD34 <sup>+</sup> Cells" <i>Journal of Hemotherapy</i> (1993) Vol. 2 pp. 221-224	<input type="checkbox"/>
	AO	Nabel, et al. "A Molecular Genetic Intervention for AIDS - Effects of a Transdominant Negative for of Rev" <i>Human Gene Therapy</i> (1994) Vol. 5 pp. 79-80	<input type="checkbox"/>
	AP	Naldini, et al. "In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector" <i>Science</i> 4/96 Vol. 272 ppl 263-267	<input type="checkbox"/>
	AQ	Poeschla, et al. "Development of HIV Vectors for Anti-HIV Gene Therapy" <i>Proc. Natl. Acad. Sci.</i> 10/1996 Vol. 93 pp.11395-11399	<input type="checkbox"/>
	AR	Tan, et al. "Inhibitory Activity of the Equine Infectious Anemia Virus Major 5' Splice Site in the Absence of Rev" <i>J. of Virology</i> 06/1996 Vol. 70 (6) pp. 3645-3658	<input type="checkbox"/>
	AS	Thierry, et al. "Systemic Gene Therapy: Biodistribution and Long-term Expression of a Transgene in Mice" <i>Proc. Natl. Acad. Sci.</i> 10/95 Vol. 92 pp. 9742-9746	<input type="checkbox"/>
	AT	Trono, et al. "HIV-1 Gag Mutants Can Dominantly Interfere with the Replication of the Wild-Type Virus" <i>Cell</i> 10/89 Vol. 59 pp.113-120	<input type="checkbox"/>
	AU	Venkatesh, et al. "Selective Induction of Toxicity to Human Cells Expressing Human Immunodeficiency Virus Type 1 Tat by a Conditionally Cytotoxic Adenovirus Vector" <i>Proc. Natl. Acad. Sci.</i> 11/1990 Vol. 87 pp.8746-8750	<input type="checkbox"/>
	AV	Youle, et al. "RNase Inhibition of Human Immunodeficiency Virus Infection of H9 Cells" <i>Proc. Natl. Acad. Sci.</i> 6/94 Vol. 91 pp. 6012-6016	<input type="checkbox"/>
	AW	Yu, et al. "Progress Towards Gene Therapy for HIV Infection" <i>Gene Therapy</i> (1994) Vol. 1 pp. 13-26	<input type="checkbox"/>
	AX	Zenke, et al. "Receptor-mediated Endocytosis of Transferrin-polycation Conjugates: An Efficient Way to Introduce DNA into Hematopoietic Cells" <i>Proc. Natl. Acad. Sci.</i> 05/90 Vol. 87 pp. 3655-3659	<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>

Examiner Signature

*E. Sorbello*

Date Considered

10-31-01

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. SF 1239052 v1

RECEIVED

AUG 21 2001